Congress fires another salvo at Allergan’s Mohawk deal; AI outfit raises $60M for discovery effort
→ Allergan’s move to try and steer around an IPR review of its patents for its $1.5 billion drug Restasis by handing them over to an Indian tribe for safekeeping was tailor made for public controversy. And lawmakers have proved obliging. Now a bipartisan group of House members are setting up a probe of the deal, which relies on the sovereign immunity of the Saint Regis Mohawk tribe to block the IPR. Allergan CEO Brent Saunders wants this to be a fight about the IPR process — what he’s wound up with is a PR battle with almost no chance of winning.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.